Novartis’s Gilenya MS Drug Has 10,000 Users in U.S., Mundel Says

Novartis AG’s Gilenya multiple sclerosis pill is “doing very well” in the U.S., with more than 10,000 patients using the treatment, the Swiss drugmaker’s head of development said.

Novartis has been “very diligent” in tracking down side effects and has found the compound’s safety profile to be consistent with the Basel-based drugmaker’s data, Trevor Mundel, the development chief, said today in a phone interview.